Rating Change
UBS analysts reiterated a Buy rating on Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) on July 15, 2026.
reiterateNASDAQ:AMRX
UBS Reiterates Buy Rating on Amneal Pharmaceuticals, Inc. (AMRX)
Rating Change UBS analysts reiterated a Buy rating on Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) on July 15, 2026. Market Context Amneal Pharmaceuticals, Inc.
Market Context
Amneal Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $17.20 with a market capitalization of $4.3B.
Analyst coverage from UBS provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Amneal Pharmaceuticals, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Amneal Pharmaceuticals, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 15, 2026 | UBS | Buy | N/A |
| May 20, 2026 | Barclays | Overweight | N/A |
| Apr 17, 2026 | UBS | Buy | N/A |
| Mar 02, 2026 | Truist Securities | Buy | N/A |
| Dec 09, 2025 | Barclays | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View AMRX Stock Page
Frequently Asked Questions
What does a Buy rating mean for AMRX?
A Buy rating from UBS reflects the analyst's outlook on Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the AMRX forecast page.